Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration | Business Wire
Sage Therapeutics' Deal With Biogen Should Revive It (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics and Biogen pursue FDA approval for zuranolone
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
sage-10k_20191231.htm
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder | Business Wire
Sage And Axsome Face Off In Depression (NASDAQ:AXSM) | Seeking Alpha
Biogen and Sage Therapeutics Complete Rolling Submission of New Drug Application for Zuranolone in the Treatment of Major Depressive Disorder and Postpartum Depression | Biogen
Sage Therapeutics Announces Development Plan for Zuranolone (SAGE-217) Following Breakthrough Therapy Guidance Meeting with the U.S. Food & Drug Administration-CliniExpert
Sage Therapeutics Announces Second Quarter 2018 Financial Results and Highlights Pipeline and Business Progress
Sage surges after depression drug gets rapid path to approval - PMLiVE
sage-10k_20181231.htm
Sage Therapeutics Forges $575 Million Deal With Shionogi to Market Depression Drug in Parts of Asia | BioSpace
On a Roll: FDA Calls Sage's Depression Drug a Breakthrough | BioSpace
Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD) | Business Wire
Sage Therapeutics: Zuranolone's Multi-Billion Dollar Market Opportunity More Than Justifies Company Valuation (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics, Shionogi ink deal for MDD treatment
Deals In Depth: November 2020 :: Generics Bulletin
Sage Therapeutics stock rockets 73% on hopes for breakthrough depression drug - MarketWatch
Sage Therapeutics Announces Promising Zuranolone Phase 3 Findings for Major Depression
Sage Therapeutics Receives FDA Breakthrough Therapy Designation for SAGE-217 for the Treatment of Major Depressive Disorder - Chemdiv
Sage Therapeutics Reports Topline Results from Pivotal Phase 3 MOUNTAIN Study of SAGE-217 in Major Depressive Disorder
Breakthrough Therapy, PRIME and Sakigake: A Comparison Between Neuroscience and Oncology in Obtaining Preferred Regulatory Status - Elena Tomaselli Muensterman, Yijia Luo, Jonathon M. Parker, 2019
Defensive Strategies For Sage Therapeutics In The Aftermath Of Potential SAGE-547 Regulatory Action (NASDAQ:SAGE) | Seeking Alpha
An Update On Sage Therapeutics (NASDAQ:SAGE) | Seeking Alpha
Sage Therapeutics' SAGE-217 fails in late-stage depression trial
